30 January 2015
We proudly announce that Malacef® (artesunate 60 mg, powder for injection) has been included on the Tableau d’honneur (Honours List) of the independent French professional journal Prescrire, for the (urgent) treatment of severe malaria caused by P.falciparum.
It is the first time since 2010 that a medicine has been included on the Tableau d’honneur. At the award ceremony, ACE was praised for making this lifesaving medicine available for the patient. Decisive was also the accessibility of this medicine and legibility of the patient information leaflet.
For a foreign firm without representative, a nomination by Prescrire is quite unique. Especially considering that Malacef is still a non-licensed medicine. Since 2007, ACE Pharmaceuticals has an Orphan Drug Designation from the European Medicines Agency for artesunate pfi.
Prescrire is known for their independent reporting. Each month, the Prescrire Editorial Staff presents systematic comparative analyses of available data on drugs newly approved in France. At the end of each year, the Palmarès Prescrire (Awards) are based on the review articles published that year.
Cees van Veldhuizen, CEO of ACE Pharmaceuticals BV and ARTECEF BV was personally invited by Prescrire to attend the award ceremony during Palmarès Prescrire 2014 in Paris, France. He is the initiator together with dr. Peter de Vries, internist, specialist in Tropical Medicine, of the introduction of this ‘lifesaving’ medicine. Since 2011, ACE is allowed to make Malacef available in French hospitals by ATU.
Palmarès Prescrire 2014 took place on 29th January 2015 and is dedicated to the most innovative medicines that represent a therapeutic advance compared with existing therapeutic options. Health authorities, medical specialists, pharmacists and the pharmaceutical industry were present at the event.